机构：[1]Department of Thoracic Surgery, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Southern Medical University, Guangzhou, China,[2]College of Medicine, Shantou University, Shantou, China,[3]Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China,[4]The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China,[5]Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, China
Background Long non-coding RNAs (lncRNAs) participate in the regulation of immune response and carcinogenesis, shaping tumor immune microenvironment, which could be utilized in the construction of prognostic signatures for non-small cell lung cancer (NSCLC) as supplements.</p> Methods Data of patients with stage I-III NSCLC was downloaded from online databases. The least absolute shrinkage and selection operator was used to construct a lncRNA-based prognostic model. Differences in tumor immune microenvironments and pathways were explored for high-risk and low-risk groups, stratified by the model. We explored the potential association between the model and immunotherapy by the tumor immune dysfunction and exclusion algorithm.</p> Results Our study extracted 15 immune-related lncRNAs to construct a prognostic model. Survival analysis suggested better survival probability in low-risk group in training and validation cohorts. The combination of tumor, node, and metastasis staging systems with immune-related lncRNA signatures presented higher prognostic efficacy than tumor, node, and metastasis staging systems. Single sample gene set enrichment analysis showed higher infiltration abundance in the low-risk group, including B cells (p<0.001), activated CD8+ T cells (p<0.01), CD4+ T cells (p<0.001), activated dendritic cells (p<0.01), and CD56+ Natural killer cells (p<0.01). Low-risk patients had significantly higher immune scores and estimated scores from the ESTIMATE algorithm. The predicted proportion of responders to immunotherapy was higher in the low-risk group. Critical pathways in the model were enriched in immune response and cytoskeleton.</p> Conclusions Our immune-related lncRNA model could describe the immune contexture of tumor microenvironments and facilitate clinical therapeutic strategies by improving the prognostic efficacy of traditional tumor staging systems.</p>
基金：
Science and
Technology Program of Guangzhou (Grant Number
201903010028) and Natural Science Foundation of Guangdong
Province, China (Grant Number 2021A1515010838).
第一作者机构：[1]Department of Thoracic Surgery, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Southern Medical University, Guangzhou, China,[2]College of Medicine, Shantou University, Shantou, China,
共同第一作者：
通讯作者：
通讯机构：[1]Department of Thoracic Surgery, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Southern Medical University, Guangzhou, China,[2]College of Medicine, Shantou University, Shantou, China,[4]The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China,[5]Department of Thoracic Surgery, Jiangxi Cancer Hospital, Nanchang, China
推荐引用方式(GB/T 7714)：
Qiaxuan Li,Lintong Yao,Zenan Lin,et al.Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.706616.
APA：
Qiaxuan Li,Lintong Yao,Zenan Lin,Fasheng Li,Daipeng Xie...&Haiyu Zhou.(2021).Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer.FRONTIERS IN ONCOLOGY,11,
MLA：
Qiaxuan Li,et al."Identification of Prognostic Model Based on Immune-Related LncRNAs in Stage I-III Non-Small Cell Lung Cancer".FRONTIERS IN ONCOLOGY 11.(2021)
